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ABSTRACT 
Background  
There is limited evidence on statin risk and effectiveness for patients aged 80+. We estimated risk 
of recurrent myocardial infarction (MI), muscle-related and other adverse events, and statin-related 
incremental costs in ‘real-world’ older patients treated with statins vs. no statins.  
Methods 
We used primary care electronic medical records from the UK Clinical Practice Research Datalink. 
Sub-hazard ratios (SHR, competing risk of death) for MI recurrence (primary endpoint), falls, 
fractures, ischemic stroke, and dementia and hazard ratios (Cox) for all-cause mortality were used 
to compare older (60+) statin users and 1:1 propensity-score-matched controls (n=12,156). 
Participants were followed-up for 10 years.   
Results 
Mean age was 76.5±9.2 years; 45.5% were women. Statins were associated with near significant 
reduction in MI recurrence (SHR=0.84, 0.69-1.02, p=0.073), with protective effect in the 60-79 age 
group (0.73, 0.57-0.94) but a non-significant result in the 80+ group (1.06, 0.78-1.44; age 
interaction p=0.094). No significant associations were found for stroke or dementia. Data suggest 
an increased risk of falls (1.36, 1.17-1.60) and fractures (1.33, 1.04-1.69) in the first two years of 
treatment, particularly in the 80+ group. Treatment was associated with lower all-cause mortality.  
Statin use was associated with healthcare cost savings in the 60-79 group but higher costs in the 80+ 
group.  
Conclusions 
Estimates of Statins effectiveness for recurrent MI prevention in patients aged 60-79 were similar to 
trial results, but more evidence is needed in the older group. There may be an excess of falls and 
fractures in very old patients, which deserves further investigation.  
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Introduction 
Statins are cholesterol-lowering drugs commonly used to prevent myocardial infarction (MI), 
ischemic stroke (ST), and other cardiovascular conditions(1). Despite their widespread use in older 
people evidence of efficacy and risks is limited for the very old and older people with significant 
comorbidities(1, 2).          
In the US from 2004 to 2009, 27% of people 55-79 years old and 24% of those aged 80 and older 
received statins(3). These figures are expected to rise significantly according to recommendations 
from current guidelines(1, 4). While statin safety and efficacy have been consistently shown in 
randomised clinical trials (RCTs) of middle-aged and generally healthy younger old people(5-8), 
evidence in the very old and in older patients with greater burden of disease is poor. RCTs on 
statins enrolled a relatively low proportion of individuals aged 75 and over (1), very few patients 
with significant comorbidity and no patient 85 and older(2). Therefore results of available RCTs 
should not be extrapolated to the general older population and additional research is needed.  
RCTs in real-world older patients are practically and ethically challenging, particularly for 
established treatments in high-risk populations, therefore observational studies evaluating the statin 
risk and effectiveness might help clarify the risk-to-benefit ratio in this group. To our knowledge, 
only one relatively small study investigated the effect of statins in preventing MI recurrence in 
‘real-world’ patients(9). This work did not account for major confounders, explore the competing 
risk of death, or investigate concurrent adverse events(9). 
Moreover, RCTs are often based on too small samples and too short follow-ups to provide robust 
evidence on adverse events. For this reason, the US Food and Drug Administration, for example, 
support the use of electronic medical record data to provide active surveillance of regulated 
medications (http://www.fda.gov/Safety/FDAsSentinelInitiative/ucm149340.htm). 
The present study was aimed to investigate the effectiveness of statins for MI recurrence prevention 
in a large sample of ‘typical’ older patients with incident MI, accounting for many potential 
5 
 
confounders and the competing risk of death. We also explored the risk of a number of conditions 
leading to disability in older age (ST, severe falls, fragility fractures, and dementia) and all-cause 
mortality, and estimated the effect of older age (80+) and burden of diseases on the association 
between statins and relevant endpoints. Finally, we investigated the incremental costs of statins. 
This was accomplished using a very-large database of GP medical records linked to hospital records 
and death certificates.  
Although the presence of residual confounding from unmeasured factors can never be entirely 
excluded in observational research, results of this study will help increase the evidence base on 
statin risks and effectiveness in typical older people and support future interventional studies in this 
section of the population. 
 
Methods 
Data source 
We used data from the UK Clinical Practice Research Datalink (CPRD), a database of anonymised 
electronic medical records collected by UK general practitioners (GPs)(10). Only data from 
practices linked to Hospital Episode Statistics (HES, for hospital records) and Office for National 
Statistics (ONS, for health certificates) databases(10) were used. The CPRD has been granted 
Multiple Research Ethics Committee approval (05/MRE04/87) to undertake purely observational 
studies and this study was approved by the Independent Scientific Advisory Committee for MHRA 
database research under protocol numbers 15_192R. 
 
Study design and study sample 
This is a quasi-experimental study designed as a retrospective parallel-cohorts study. Quasi-
experiments are studies that aim to evaluate interventions but that do not use randomization(11). All 
participants were hospitalised for first MI between 1st April 1997 (first HES data collection) and 
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31
st
 March 2014 (latest HES data collection date in the available dataset), aged 60+ years at the 
time of, and alive 4 weeks after the acute event (CONSORT diagram with participant selection 
criteria in Supplementary Figure S1).  
 
Treatment groups 
Statins (atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin), regardless of strength 
and treatment duration, represented the exposure. Lovastatin (not commercialised in the UK), 
cerivastatin (withdrawn from the market) and the association simvastatin/ezetimibe were not 
included in the analysis. Statins were coded according to Chapter 2.12 of the British National 
Formulary(12) and prescriptions derived from GP records.    
The treatment group included all participants never treated with statins before their incident MI who 
had records of statin prescription within 56 days after the acute event. The control group included 
people never treated with statins before their first MI who did not receive a prescription of statins in 
the 56 after the acute event. According to previous research(13), including ‘late’ statin users in the 
control group, allows both to simulate situations encountered during RCTs and avoid a biased 
comparison only with controls never “at risk” of being prescribed a statin. The study groups were 
followed-up from the date of incident MI (baseline), until the occurrence of the event of interest, 
death, study end (i.e. 10 years after baseline or 31st March 2014, whichever came first) or, only for 
‘late statin users’, until statin prescription. 
For the purpose of exploring drug persistence in people treated with statins, duration of treatment 
was assessed only in people alive for the entire 10-year period, as the time spanning between the 
first and the last prescription refill. 
Endpoints 
Primary endpoint was a composite of fatal MI (MI followed by death within 28 days(14)) or non-
fatal MI.  We used only episodes of MI leading to hospitalisation and reported in HES records, to 
minimise misclassification given the low specificity of MI diagnosis in CPRD(15).  
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Secondary endpoints were ST, severe falls (requiring hospital admission), fragility fractures (spine, 
hip, wrist, humerus, pelvis, and ribs, requiring hospitalisation), dementia, and all-cause mortality. 
These conditions were coded using ICD-10 for ST and severe falls and ICD-10 + OPCS-4 codes for 
fractures and derived from HES database. Dementia was coded using GP (“Read codes” adapted for 
CPRD) and/or HES records (ICD-10). All-cause mortality was ascertained using a combination of 
both ONS and GP records. Analyses of all secondary endpoints were hypothesis generating and 
excluded people with the relevant condition at baseline. 
 
Covariates 
We used a set of 73 characteristics/conditions including enrolment period, demographics, traditional 
risk factors, diseases, drugs, and measures of healthcare utilisation (those included in table 1) as 
covariates to ensure an adequate control of confounding, according to previous work(16). 
Covariates were coded by combining GP and HES data to reduce misclassification.  
Healthcare costs, including statins and other medications(17), relevant monitoring tests(4), GP visits 
recorded(18), outpatient(18) and inpatients(19) hospital attendances were calculated based on GP 
and HES recorded events. Drugs were coded using the British National Formulary(12) and 
prescriptions derived from GP records.    
 
Statistical analysis 
Baseline differences of both non-matched and matched samples were reported as mean and standard 
deviation (SD) or percentages and compared using analysis of variance (ANOVA) or chi-square test 
as appropriate.  
Groups were matched 1:1 using propensity score, based on 60 of the 73 covariates initially listed 
(those independently associated with exposure and/or primary outcome plus a few variables 
included regardless their lack of association because of their potential confounding effect).  
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Endpoint analyses used survival analysis with competing risk models(20), to account for the high 
frequency of death within this age group, and results were reported as Sub-hazard ratios (SHR) and 
95% confidence intervals (95%CI), according to Fine and Gray(21). Cox proportional hazard 
models (using practice ID as strata) were used to analyse all-cause mortality and results were 
displayed as hazard ratios (HR) and 95%CIs. 
Data were analysed by censoring follow-up time of ‘late users’ (control group only) when statin 
prescription was issued according to previous research(13). Alternate results obtained without this 
censoring were also presented as supplementary material.   
Analyses on MI, ST, dementia, and all-cause mortality excluded events occurring the first two years 
of follow-up. Exclusion of the first two years of follow-up was based on exploratory analyses (data 
not shown) and meant to i) reduce “reverse causation’ issues (people more likely to die in the short 
period were less likely to be treated and patients more likely to have immediate MI recurrence were 
more likely to receive statins), ii) reduce the confounding effect of early non-atherosclerotic 
coronary events (i.e. restenosis or late stent thrombosis) and iii) account for the timing of statin 
effect on cardiovascular outcomes that is likely to be apparent many years after treatment 
initiation(5). The main model for falls and fractures included the first two years of follow-up based 
on considerations regarding the shorter timing of statins effects on skeletal muscle. Results from 
alternate models including first two years of follow-up for MI, ST, dementia and all-cause mortality 
and excluding the first two years of follow-up for falls and fractures were also presented as 
supplementary material.    
To investigate the effect of age and burden of disease on outcomes, using interactions terms, 
participants were divided  into age (60-79 and 80+) and disease burden groups. The Charlson 
Comorbidity Index was used to assess disease burden since as this tool was adapted and validated in 
the CPRD(22). Patients divided into two disease burden groups (Charlson Index: <5, fist three 
quartiles, and ≥5, last quartile(22)). Age and disease burden analyses were not data-driven but pre-
specified in the approved protocol, as one of the main objects of the present research.   
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A similar analysis investigated the effect of post-MI revascularisation procedures (percutaneous 
transluminal coronary angioplasty or coronary artery by-pass graft) on the association between 
statins and recurrent MI.  
Numbers needed to treat were calculated using a published formula(23). 
An alpha level of 0.05 was chosen as the threshold for statistical significance for the primary 
endpoint and a 0.10 level for interaction terms. All secondary endpoint analyses were considered 
exploratory. 
Data were analysed using the Stata 13 (StataCorp. 2013. Stata Statistical Software: Release 13. 
College Station, TX: StataCorp LP).   
 
Results 
Sample characteristics 
After propensity score matching, the study sample included 12,156 people (6,078 per group). Mean 
age at baseline was 76.5 (SD: 9.2), ranging from 60 to 105.4 years, women comprised 45.5% of the 
sample.  
In the treatment group, 78.1% of patients received one statin, 18.9% two, and the remaining three or 
four. Of those who received one statin, 65% were treated with simvastatin, 28.9% with atorvastatin, 
and the remaining with pravastatin, fluvastatin, or rosuvastatin. In the control group, 42.6% of the 
patients received statin treatment ≥57 days after the acute event. Of these ‘late’ statin users, 29.8% 
received statins within the first 3 months, 34.5% within the first year, and the remaining 36.1% 
from 1 to 10 years after the first MI.  
Eighty percent of participants aged 60-79 years and 58% of those aged 80+ and over who were 
alive for the entire 10-year follow-up were still on statins two years after the incident MI; these 
proportions decreased to 67.6% and 35.2% at year 4 and to 58.6 and to 20.9 respectively at year 6.     
After matching, study groups did not differ for any of the 73 measured baseline characteristics 
(Table 1).  
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Primary endpoint 
Figure 1 shows SHRs and 95% CI for recurrent MI for the whole study sample and by age and 
disease burden group. Patients were followed-up for 43,314 person-years. The rate of MI recurrence 
was 19.2 per 1,000 person-years (831 MIs). People treated with statins were less likely to have MI 
recurrence, although the association was only marginally significant in the whole sample. Statins 
showed a significant benefit in the 60-79 but not in the 80+ group. Disease burden did not affect the 
estimates.  
Number needed to treat for MI recurrence was 154.6 (104.5-248.2); Undergoing revascularisation 
was associated with better statin effectiveness (revascularisation: SHR=0.41, 95%CI=0.27-0.51, 
p<0.001; no revascularisation: 0.95, 0.76-1.19, p=0.685; p for interaction=0.003).  
When the first two years of follow-up were included in the analysis (Supplementary Table S1), 
statins were associated with a greater MI risk, particularly in older people (60-79: 0.99, 0.81-1.21, 
p=0.976; 80+: 1.46, 1.18-1.81, p<0.001; p for interaction=0.025).    
 
Secondary endpoints   
The incidence rate for ST was 7.1 per 1,000 person-years (n=196 cases), for dementia was 16.7 
(n=446); for severe falls was 24.8 (n=1,026 episodes); for fragility fractures was 7.6 (n=322) and 
all-cause mortality rate was 115.1 (n=5,165) per 1,000 person-years.  
Figure 2 shows SHR and 95%CI for ST, dementia, falls and fractures. No association was found 
between ST and dementia. People treated with statins were at greater risk of severe falls and 
fragility fractures.  
The risk of falls (60-79: 1.13, 0.91-1.40, p=0.260; 80+: 1.82, 1.45 to 2.30, p<0.001; p for 
interaction=0.012) and fractures (60-79: 1.00, 0.70-1.41, p=0.993; 80+: 1.91, 1.36-2.67, p<0.001; p 
for interaction=0.019) was greater in people 80+ then in their younger counterparts.  
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Although the estimates were not significant, SHRs for ST were lower in the 60-79 than in the 80+ 
group (60-79: 0.73, 0.42-1.14, p=0.168; 80+: 1.37, 0.81-2.33; p for interaction=0.098).  
No interaction with age was found for dementia. Burden of diseases did not affect the estimates of 
ST, dementia, falls and fractures (data not shown).    
When events occurring during the first two years of follow-up were excluded from the analysis, 
people in the treatment group were less likely to fall than those in the control group (0.73, 0.64 to 
0.85, p<0.001) (Supplementary Table S2). 
Participants in the statin group had lower risk for all-cause mortality (HR=0.62, 0.57 to 0.68, 
p<0.001). Increasing age (60-79: 0.62, 0.55 to 0.72, p<0.001; 80+ and over: 0.77, 0.67 to 0.89, 
p<0.001; p for interaction=0.010), but not burden of disease, affected the association between 
statins and all-cause mortality. When follow-up of statin-treated controls was not censored at the 
time of statin initiation, the benefit of statins on all-cause mortality was substantially attenuated 
(HR=0.83, 0.78 to 0.90; p<0.001).  
 
Costs 
Over 10 years, mean total cost per patient in the statin group was £24,011 (~$36,000, at exchange 
rate of 1.50 $ per 1 £). For the control group the mean total cost was £23,094 (~$34,700). The mean 
cost difference between the groups was £917 (-3,930-5,630) (~$1,400) per patient per annum. In the 
60-79 age group, statins resulted in cost savings of -£13,234 (-35,122-2,287) (~$20,000) but 
increased costs in the 80+ group £6,729 (5,099-8,265) (~$10,000).    
Same associations but lower estimates were found when follow-up of people taking statins in the 
control group was not censored at the time of statin prescription. Overall mean cost difference was -
£176 (-2,299-1,789) reflecting a cross-over use of statins by 42% (2564/6078) of subjects in the 
control group after the start of the observation period. The mean cost difference between the groups 
was £92 per patient per annum. In the 60-79 age group, statins resulted in cost savings of £-3,962 (-
8,012- -175) but increased costs in the 80+ group £3,377 (1,319-5,077).  
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Discussion 
To our knowledge, this is the first study investigating statin effectiveness for the prevention of MI 
recurrence in a large sample of ‘real-world’ older people with incident MI, accounting for a large 
number of covariates and exploring the competing risk of death. Results showed that statins were 
effective in younger old people in reducing recurrent MI, with similar effect sizes to those from 
RCTs. In testing for interactions with advanced age, we found evidence of more modest protective 
effects in the older group, but  confidence intervals were wide and more evidence will be needed to 
clarify the effect sizes. Burden of disease did not affect the estimates. Undergoing post-MI 
revascularisation was associated with greater statin benefit.  
Risk of falls and fractures might be higher, particularly in the very old during the first years of 
treatment. No association with ST or dementia was found. Finally, people treated with statins were 
at lower risk of all-cause mortality and yet, the benefit was lower in the very old. Statin treatment 
was associated with cost-savings in the 60-79 but higher costs in the 80+ group. 
Data on older people have been provided in RCTs on statins including both primary and secondary 
prevention patients(24-26) and results are not easy to directly compare. Overall, our estimates for 
the primary endpoint (MI) are similar to those of RCTs on statins in the age group (60-79) usually 
enrolled in RCTs (5). To the best of our knowledge, only one observational study has evaluated the 
effectiveness of statins on the prevention of MI recurrence in ‘real-world’ older patients(9). In this 
study, conducted in a relatively small sample (n=1,410) of older patients, the authors found that, 
after adjusting for age, smoking habit, hypertension, diabetes, and LDL and HDL cholesterol levels, 
people in the statin group were less likely to develop fatal and non-fatal MI than people in the 
control group (Relative Risk=0.49, 0.43-0.57)(9). Given the limited number of potential 
confounders included in the analysis, the risk of residual confounding, particularly ‘reverse 
causation’, cannot be excluded in this study. 
13 
 
As expected, statin treatment immediately after MI was probably driven by a combination of better 
short-term prognosis (~4-fold greater first-year mortality rates in controls, data not shown) and 
greater risk of imminent MI recurrence (increased MI risk associated with statins when events 
occurred in the first years were included).  
The fact that statin benefit might decrease in older age has been considered biologically plausible 
and previously reported in studies on statins and mortality(27). Of note, age also markedly affects 
the association between cholesterol levels and mortality for ischemic heart disease(28). However, 
we cannot exclude that the observed reduced benefit in people 80+ might result from poor treatment 
persistence.   
All secondary endpoint analyses of this study should be considered exploratory.  
Our results showed that statin was not associated with dementia risk. This is in line with a recent 
Cochrane review(29). The lack of association with ischemic stroke requires consideration. Although 
not significant, estimates obtained in the 60-79 group are similar to those of RCTs and our study 
was not powered to capture such an effect with small number of events.    
We found increased risk in falls and fractures, especially in people 80+ during the first treatment 
years. Statins can cause myopathy, from subclinical to life-threatening forms and age and 
comorbidity are important risk factors (30). Its consequences in vulnerable older people can 
potentially be more dangerous than in younger/healthier older patients. While statin use has been 
associated with lower energy and greater muscle exertion(31), longitudinal decrease in muscle 
performance, and increased risk of falls in small studies of older people(32), other authors found no 
association(33), or even benefit on skeletal muscle(34). The fact that statins are protective from falls 
after the first two years, when follow-up time in statin-prescribed controls was not censored, is not 
easy to explain. This might result from a combination of fall rate reduction in the treatment group 
after the second year of follow up (discontinuation of treatment in case of adverse reactions and/or 
timing of muscle damaging effect) and concurrent fall rate increase among ‘late statin users’ (once 
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they start receiving treatment) in the control group that could not be captured when ‘late statin 
users’ follow-up time was censured. Alternatively, when taken for longer periods, statins might 
reduce the fall risk by slowing the decline of cardiovascular function.  
A number of studies have investigated the association between statin use and all-cause mortality 
(27) in older people with previous cardiovascular disease. Our estimates were remarkably consistent 
with those of most published reports (27). The fact that estimates of statin benefit for all-cause 
mortality is greater than that for MI recurrence might be explained by long-term non-cardiovascular 
beneficial statin effects such as those on cancer(35); however, we cannot exclude the presence of 
residual confounding.         
Previous modelling studies (36) found that statin therapy for secondary prevention is associated 
with increased costs to the health care system. In contrast, this analysis presents evidence from 10 
years observational follow-up that statins may result in cost savings in people aged 60-79 but 
increased costs in 80+. These results warrant further cost-effectiveness analysis that accounts for 
the accrual of healthcare costs and quantity and quality of life benefits to patients.                            
There are inevitably limitations in the analysis presented. While statin prescription and the main 
conditions studied are likely to be accurately ascertained in the combination of primary care and 
hospital inpatient records used, there may be some under-diagnosis of dementia and under-
recording of falls, but there is no apparent reason why these limitations would be associated with 
statin receipt after MI. The propensity scoring approach models effects only in those cases and 
controls that have overlapping scores, reducing the sample size analysed, although the patients 
included in analyses are those for whom clinical decisions about adding in statins varied after 
myocardial infarction in apparently similar cases.  
Observational analyses like the one presented here are always limited in not being able to 
definitively exclude the existence of residual confounding that might have resulted from 
unmeasured factors, although the very high number of variables used in our propensity scoring 
15 
 
should have minimised such biases. Given that the statin treated group enjoyed lower mortality 
rates during the up to 10 year follow-up, the observed associations with injurious falls and fractures 
are unlikely to have been driven by a general excess morbidity in the statins group, but appear to be 
a specific effect that is difficult to explain by residual negative health difference between the statin 
treated patients and their controls, after matching. The main analysis for the primary endpoint (MI 
recurrence) excluded the first two years of follow-up and therefore the results obtained cannot be 
generalisable to the early period of treatment. However, since the beneficial effect of statins for 
cardiovascular prevention occurs 1-3 years after treatment start(5) we are confident that this 
exclusion, while helpful to address reverse causation, did not significantly bias the primary endpoint 
estimates. Finally, a number of unmeasured factors might have contributed to the high “noise-to-
signal” ratio reflected by the large variability and confidence intervals in our real-world older 
people. While an “a priori” sample size calculation was performed based on the point estimates 
obtained by Baigent and colleagues(5), given the greater proportion of older patients  in our sample 
and higher heterogeneity seen in this group, we cannot exclude that the overall primary endpoint 
analysis was slightly underpowered.                  
Along with the limitations, it is worth noting that the analysis includes all eligible patients in the 
dataset (i.e. the equivalent of a 100% response rate) and likely negligible loss to follow-up in 
hospital and death certificate data during our up to ten year analysis of outcomes. The estimates 
produced are therefore likely to represent ‘real world’ outcomes in typical clinical practice during 
the period studied. Also worth noting is that we have not excluded frail or dependent groups 
including those in nursing and residential homes.  
Further work, including RCTs, is needed to replicate these findings in independent populations and 
to clarify the mechanisms of the excess falls and fractures, establishing whether these are driven by 
the well-known effects of statins on muscle or through other mechanisms in older people.   
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In conclusion, our quasi-experimental analysis of effectiveness of statins for secondary prevention 
of myocardial infarction produced estimates in line with results of RCTs for patients aged 60 to 79, 
but more evidence is needed in the older groups. We found evidence of excess falls and fractures in 
very old patients, which deserve further investigation. If these results are confirmed, higher falls 
and fracture rates need to be considered in judgements about the appropriateness of statin use in 
older patients.  Very old patients in our analysis were less likely to stay on treatment for a period 
long enough to provide benefit but long enough to risk serious adverse reactions.    
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Table 1: Characteristics of the matched sample at baseline by treatment group 
 
        
    
Characteristic Controls Statins 
p-
value 
        
    Number 6,078 6,078 
 Enrolment year (%) 
  
0.797 
1997-2001 34.7 35.5 
 2002-2005 25.0 24.9 
 2006-2009 18.2 17.9 
 2010-2014 22.2 21.7 
 Demographics 
Age at baseline [years, mean (SD)] 76.4 (9.4) 76.5 (8.9) 0.555 
Age category (%) 
  
0.312 
60-79 61.8 62.6 
 80+ 38.3 37.4 
 Gender (%, women) 45.5 45.5 0.956 
Ethnicity (%) 
  
0.888 
White 82.9 82.7 
 Non-white 2.1 2.2 
 Undisclosed/Unreported 15.0 15.1 
 Index of multiple deprivations (%) 
  
0.978 
First quintile (least deprived) 19.7 19.5 
 Second 24.3 24.4 
 Third 21.2 21.6 
 Fourth 20.5 20.0 
 Fifth quintile (most deprived) 14.1 14.4 
 Undisclosed/Unreported 0.20 0.20 
 Cardiovascular risk factors 
Smoking status (%) 
  
0.845 
Never 33.1 33.1 
 Former 25.4 25.7 
 Current 39.2 39.2 
 Undetermined 2.3 2.0 
 Drinking habit (%) 
  
0.978 
Never 13.7 13.9 
 Current normal amount 42.2 41.6 
 Current, unknown amount 1.0 1.0 
 Current, heavy drinker 8.3 8.4 
 Former 2.4 2.5 
 Undetermined 32.5 32.6 
 Body Mass Index (%) 
  
0.869 
18.4 or below 1.9 1.7 
 18.5-24.9 20.9 20.9 
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25-29.9 21.1 20.5 
 30 or over 9.6 9.9 
 Unmeasured 46.5 47.0 
 Total cholesterol level [(in mmol/l), %] 
  
0.643 
lower than 6.2 (=240 mg/dl) 27.4 28.2 
 6.2 or higher 8.4 8.2 
 Unmeasured 64.1 63.6 
 Health care utilisation and measures of disease burden 
Flu vaccination (%) 
  
0.514 
Received (in the previous year) 48.4 49.4 
 Not received (in the previous year) 35.1 34.7 
 Never received 16.4 15.9 
 Number of drugs (%) 
  
0.256 
 0-1 21.1 20.3 
  2-4 19.2 18.3 
  5-9 26.9 27.8 
 more than 10 32.7 33.6 
 Charlson Index (%) 
  
0.947 
0 30.5 30.2 
 1-2 33.4 33.2 
  3-4  14.8 15.1 
 5 or more 21.3 21.5 
 Nursing home visits [(previous year), %] 0.3 0.3 1.000 
Residential home visits [(previous year), %] 0.4 0.3 0.375 
More than 4 GP consultations [(previous year), %] 51.6 52.2 0.502 
Any hospitalisation [(previous year), %] 15.8 16.2 0.553 
Any geriatrics referral [(previous year), %] 0.9 1.1 0.311 
Any cardiology referral [(previous year), %] 1.4 1.5 0.445 
Revascularisation procedures before MI [(non-myocardial-
infarction reason reasons, previous year), %] 0.3 0.3 0.862 
Diseases at baseline 
Hypertension (%) 40.0 40.7 0.437 
Diabetes (%) 5.3 5.7 0.248 
Stroke/Transient ischemic attack (%) 8.1 8.1 0.973 
Congestive heart failure (all stages, %) 43.7 43.8 0.869 
Atrial fibrillation (%) 8.5 8.9 0.479 
Heart failure (%) 7.7 8.1 0.479 
Asthma (%) 11.1 10.6 0.414 
Chronic Obstructive Pulmonary Disease (%) 9.1 8.9 0.704 
Chronic Kidney Diseases (stage 3-5, (%) 6.5 6.8 0.513 
Cancer (%) 9.0 9.2 0.614 
Dementia (%) 1.7 1.8 0.682 
Depression (%) 14.2 14.7 0.470 
Mental health condition (%) 1.2 1.3 0.742 
19 
 
Epilepsy (%) 1.4 1.4 0.938 
Hypothyroidism (%) 6.6 6.7 0.856 
Incontinence (%) 5.7 5.9 0.669 
Osteoporosis (%) 5.3 5.3 0.903 
Osteoarthritis (%) 26.3 26.7 0.608 
Falls (%) 18.4 18.6 0.833 
Fractures (%) 4.7 4.5 0.603 
Cirrhosis (%) 0.2 0.3 0.563 
Drugs at baseline 
Angiotensin converting enzyme inhibitors (%) 11.3 11.6 0.512 
Angiotensin Receptors Blockers (%) 2.6 3.1 0.103 
Renin inhibitors (%) 0.0 0.0 0.317 
Calcium channel blockers (%) 6.6 6.9 0.406 
Beta-blockers 9.6 10.6 0.071 
Alpha-adrenoceptor blocking drugs (%) 2.1 2.2 0.573 
Centrally acting antihypertensive drugs (%) 0.2 0.2 0.835 
Non-loop Diuretics (%) 6.9 7.2 0.457 
Potassium sparring agents (%) 3.0 2.7 0.254 
Loop diuretics (%) 16.5 17.2 0.265 
Anti-platelets (%) 22.3 23.5 0.142 
Oral anticoagulants (%) 2.6 2.9 0.315 
Nitrates (%) 9.3 10.1 0.133 
Digoxin (%) 3.3 3.5 0.726 
Anti-arrhythmic drugs (%)  0.9 0.8 0.493 
Insulin (%) 1.6 1.5 0.770 
Sulphonylureas (%) 2.8 3.1 0.286 
Metformin (%) 2.9 3.0 0.708 
Other antidiabetic drugs 0.2 0.2 0.414 
Corticosteroids (including topical and inhaled) (%) 26.6 27.3 0.347 
Oestrogens (%) 0.9 0.9 0.923 
Testosterone (%) 0.0 0.1 0.414 
Proton pump inhibitors (%) 16.6 17.8 0.071 
H2-receptor antagonists (%) 3.9 4.0 0.852 
First generation antipsychotic drugs (%) 4.8 5.2 0.262 
Second generation antipsychotic drugs (%) 0.5 0.6 0.709 
Tricyclic antidepressants (%) 5.2 5.0 0.622 
Selective Serotonin Reuptake Inhibitors (%) 4.0 4.5 0.209 
Other antidepressants (%) 1.1 1.1 0.861 
Anti-cholinesterase drugs (%) 0.3 0.4 0.876 
Cytochrome P450 inhibiting drugs (%) 13.2 13.8 0.34 
Anti-Parkinson's drugs (%) 2.0 2.0 0.948 
Drugs for incontinence (%) 3.4 3.7 0.303 
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Figure legends  
 
Figure 1:  
Effectiveness of statins for prevention of recurrence of MI in the whole sample (60+) and by 
age and disease burden group (competing risk of death, excluding first 2 years’ events)   
 
Figure 2:  
Risk of disabling conditions of older age in the whole sample (60+, competing risk of death, 
excluding first 2 years’ events for ischemic stroke and dementia)    
 
 
 
 
 
 
 
 
 
 
 
